WO2009017716A3 - Pulsatile gastric retentive dosage forms - Google Patents
Pulsatile gastric retentive dosage forms Download PDFInfo
- Publication number
- WO2009017716A3 WO2009017716A3 PCT/US2008/009139 US2008009139W WO2009017716A3 WO 2009017716 A3 WO2009017716 A3 WO 2009017716A3 US 2008009139 W US2008009139 W US 2008009139W WO 2009017716 A3 WO2009017716 A3 WO 2009017716A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage forms
- gastric retentive
- stomach
- administration
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008801008164A CN101888828A (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms |
CA2694602A CA2694602A1 (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms |
EP08794829A EP2192892A2 (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms |
MX2010001071A MX2010001071A (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms. |
AU2008282900A AU2008282900B2 (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms |
JP2010519222A JP2010534721A (en) | 2007-07-27 | 2008-07-25 | Pulse type gastric retentive preparation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95250107P | 2007-07-27 | 2007-07-27 | |
US60/952,501 | 2007-07-27 | ||
US96771707P | 2007-09-05 | 2007-09-05 | |
US60/967,717 | 2007-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009017716A2 WO2009017716A2 (en) | 2009-02-05 |
WO2009017716A3 true WO2009017716A3 (en) | 2009-07-30 |
Family
ID=40219415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/009139 WO2009017716A2 (en) | 2007-07-27 | 2008-07-25 | Pulsatile gastric retentive dosage forms |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090028941A1 (en) |
EP (1) | EP2192892A2 (en) |
JP (1) | JP2010534721A (en) |
CN (1) | CN101888828A (en) |
AU (1) | AU2008282900B2 (en) |
CA (1) | CA2694602A1 (en) |
MX (1) | MX2010001071A (en) |
WO (1) | WO2009017716A2 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITFI20070253A1 (en) * | 2007-11-09 | 2009-05-10 | Valpharma Internat S P A | PHARMACEUTICAL FORMULATIONS FOR THE ADMINISTRATION OF IPP. |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2720108C (en) | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CN102046154A (en) * | 2008-06-03 | 2011-05-04 | 诺瓦提斯公司 | Pulsatile release of valsartan |
WO2010018593A2 (en) * | 2008-07-03 | 2010-02-18 | Torrent Pharmaceuticals Ltd. | Gastric acid resistant benzimidazole multiple unit tablet composition |
WO2010019915A1 (en) | 2008-08-15 | 2010-02-18 | Depomed Inc. | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders |
FR2949061B1 (en) * | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | FLOATING MICROGRANULES |
WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
US20110052685A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US20110104272A1 (en) * | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US20110287096A1 (en) * | 2010-05-18 | 2011-11-24 | Abon Pharmaceuticals, Llc | Modified gastroretentive drug delivery system for amine drugs |
CA2808546C (en) | 2010-08-18 | 2018-02-20 | Evonik Roehm Gmbh | Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid |
CA2850468C (en) | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
WO2012092486A2 (en) * | 2010-12-29 | 2012-07-05 | Dr. Reddy's Laboratories Ltd. | Modified release benzimidazole formulations |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US9439860B2 (en) | 2012-06-25 | 2016-09-13 | Mylan, Inc. | Fenofibrate formulation |
US8722083B2 (en) * | 2012-06-25 | 2014-05-13 | Mylan, Inc. | Fenofibrate formulation |
KR102062357B1 (en) | 2013-02-13 | 2020-01-03 | 레드힐 바이오파마 엘티디 | Pharmaceutical compositions for the treatment of helicobacter pylori |
CN107530289A (en) * | 2015-02-27 | 2018-01-02 | 扣带回治疗学有限公司 | Three pulse release excitement agent formulations |
CA2977168C (en) * | 2015-03-31 | 2020-01-28 | Laboratorios Bago S.A. | Enteric-coated pellets containing a proton pump inhibitor |
CN106236715B (en) * | 2015-06-03 | 2021-05-07 | 南京三迭纪医药科技有限公司 | Pharmaceutical dosage forms and uses thereof |
JP6657974B2 (en) * | 2016-01-12 | 2020-03-04 | トヨタ紡織株式会社 | Metal-resin integrated molded product and method of manufacturing the same |
KR101884230B1 (en) * | 2016-02-29 | 2018-08-01 | 주식회사 유영제약 | Formulation containing esomeprazole |
US10327994B2 (en) * | 2016-05-02 | 2019-06-25 | Dose Pack Llc | System and methods for customized medicine dosages in a capsule |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
JP7071748B2 (en) * | 2016-12-02 | 2022-05-19 | クレキシオ バイオサイエンシーズ エルティーディー. | Gastric retention system |
CN108956912A (en) * | 2017-05-17 | 2018-12-07 | 亚宝药业集团股份有限公司 | A kind of measuring method of Nifedipine sustained release tablets dissolution curve |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
CA3031412C (en) | 2017-06-16 | 2020-08-11 | Kashiv Pharma Llc | Gastroretentive dosage forms for sustained drug delivery |
US20210145777A1 (en) * | 2017-06-16 | 2021-05-20 | Altibio, Inc. | Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders |
US11229606B2 (en) | 2018-06-18 | 2022-01-25 | Amneal Complex Products Research Llc | Extended release compositions comprising pyridostigmine |
US20230041197A1 (en) * | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20210196627A1 (en) * | 2018-08-15 | 2021-07-01 | Lyndra, Inc. | Systems for enteric delivery of therapeutic agents |
CN111141854A (en) * | 2018-11-06 | 2020-05-12 | 中国科学院大连化学物理研究所 | Method for simultaneously extracting polar and low-polar metabolites from biological sample |
CN110372869B (en) * | 2019-08-24 | 2021-08-27 | 思必康(厦门)新材料有限公司 | Polyvinyl alcohol-heparin polymer and preparation method and application thereof |
US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4487327A (en) * | 1982-12-21 | 1984-12-11 | Grayson Robert E | Locking capsule |
WO1988001160A1 (en) * | 1986-08-19 | 1988-02-25 | Hughes Raymond J | Tamper evident capsule and insert device |
US4764380A (en) * | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
EP0669129A2 (en) * | 1994-02-28 | 1995-08-30 | Bayer Ag | Expandable release controlled medicaments |
WO1998011879A1 (en) * | 1996-09-19 | 1998-03-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
WO1999007342A1 (en) * | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
WO1999033446A1 (en) * | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
WO2003035041A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
WO2005079384A2 (en) * | 2004-02-13 | 2005-09-01 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Expandable gastric retention device |
WO2007083309A2 (en) * | 2006-01-18 | 2007-07-26 | Intec Pharma Ltd. | Method and apparatus for forming delivery devices for oral intake of an agent |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
AT397345B (en) * | 1990-04-04 | 1994-03-25 | Chemiefaser Lenzing Ag | PHARMACEUTICAL PREPARATION WITH DELAYED ACTIVE SUBSTANCE RELEASE BASED ON HEMICELLULOSES |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
SE9704870D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6098629A (en) * | 1999-04-07 | 2000-08-08 | Endonetics, Inc. | Submucosal esophageal bulking device |
MXPA02007254A (en) * | 2000-02-04 | 2002-12-09 | Depomed Inc | Shell and core dosage form approaching zero order drug release. |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
AU6872201A (en) * | 2000-06-23 | 2002-01-08 | Teva Pharma | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
EP1738751B1 (en) * | 2001-01-12 | 2011-05-11 | Sun Pharma Advanced Research Company Ltd | Spaced drug delivery system |
CA2449009A1 (en) * | 2001-05-29 | 2002-12-05 | Depomed Development, Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
CN1520286B (en) * | 2001-07-04 | 2010-12-01 | 太阳医药工业有限公司 | Gastric retention controlled drug delivery system |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
ITMI20012481A1 (en) * | 2001-11-23 | 2003-05-23 | Univ Parma | MODULAR SYSTEMS FOR THE CONTROLLED RELEASE OF SUBSTANCE WITH SPATIAL AND TEMPORAL CONTROL |
US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
US20060135406A1 (en) * | 2002-10-14 | 2006-06-22 | Sabina Glozman | Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
KR20060083198A (en) * | 2003-08-27 | 2006-07-20 | 벡타 리미티드 | Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
US20050249806A1 (en) * | 2004-02-10 | 2005-11-10 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug |
EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
AR052225A1 (en) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | FORMULATIONS OF MODIFIED RELEASE TABLETS FOR INHIBITORS OF THE PUMP OF PROTONS |
US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
RU2467740C2 (en) * | 2005-12-28 | 2012-11-27 | Такеда Фармасьютикал Компани Лимитед | Controlled release solid drug |
EP1973530A2 (en) * | 2005-12-30 | 2008-10-01 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
-
2008
- 2008-07-25 JP JP2010519222A patent/JP2010534721A/en active Pending
- 2008-07-25 WO PCT/US2008/009139 patent/WO2009017716A2/en active Application Filing
- 2008-07-25 AU AU2008282900A patent/AU2008282900B2/en not_active Ceased
- 2008-07-25 CN CN2008801008164A patent/CN101888828A/en active Pending
- 2008-07-25 US US12/220,747 patent/US20090028941A1/en not_active Abandoned
- 2008-07-25 MX MX2010001071A patent/MX2010001071A/en not_active Application Discontinuation
- 2008-07-25 CA CA2694602A patent/CA2694602A1/en not_active Abandoned
- 2008-07-25 EP EP08794829A patent/EP2192892A2/en not_active Withdrawn
-
2015
- 2015-08-27 US US14/838,031 patent/US20160038411A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4764380A (en) * | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
US4487327A (en) * | 1982-12-21 | 1984-12-11 | Grayson Robert E | Locking capsule |
WO1988001160A1 (en) * | 1986-08-19 | 1988-02-25 | Hughes Raymond J | Tamper evident capsule and insert device |
EP0669129A2 (en) * | 1994-02-28 | 1995-08-30 | Bayer Ag | Expandable release controlled medicaments |
WO1998011879A1 (en) * | 1996-09-19 | 1998-03-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
WO1999007342A1 (en) * | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
WO1999033446A1 (en) * | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
WO2003035041A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
WO2005079384A2 (en) * | 2004-02-13 | 2005-09-01 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Expandable gastric retention device |
WO2007083309A2 (en) * | 2006-01-18 | 2007-07-26 | Intec Pharma Ltd. | Method and apparatus for forming delivery devices for oral intake of an agent |
Also Published As
Publication number | Publication date |
---|---|
WO2009017716A2 (en) | 2009-02-05 |
JP2010534721A (en) | 2010-11-11 |
US20090028941A1 (en) | 2009-01-29 |
MX2010001071A (en) | 2010-03-09 |
CN101888828A (en) | 2010-11-17 |
CA2694602A1 (en) | 2009-02-05 |
EP2192892A2 (en) | 2010-06-09 |
US20160038411A1 (en) | 2016-02-11 |
AU2008282900B2 (en) | 2014-05-22 |
AU2008282900A1 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009017716A3 (en) | Pulsatile gastric retentive dosage forms | |
WO2010062688A3 (en) | Dosage form for insertion into the mouth | |
WO2010114425A3 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
HRP20151437T1 (en) | Fast acting inhibitor of gastric acid secretion | |
IL199234A (en) | Crystalline form of racemic ilaprazole, pharmaceutical compositions comprising it for inhibiting gastric acid secretion and use thereof in the preparation of medicaments for treating gastrointestinal inflammatory disorders | |
HRP20120754T1 (en) | Dosage form containing pantoprazole as active ingredient | |
WO2012117257A8 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
NZ597534A (en) | Method for treating a patient in need of aspirin therapy | |
HRP20211046T1 (en) | Uses of benzimidazole derivative for nocturnal acid breakthrough | |
NO20075393L (en) | Acarbose-based methods and designs for the treatment of chronic constipation | |
CN102397277A (en) | Esomeprazole-containing medicinal composition | |
JP2014240435A (en) | Compositions and methods for inhibiting gastric acid secretion | |
AU2016277587B2 (en) | Buffered upper GI absorption promoter | |
WO2010117756A3 (en) | Substituted benzimidazole pharmaceutical formulations | |
RU2005122465A (en) | (-) - TENATOPRAZOL ENANTIOMER AND ITS APPLICATION IN THERAPY | |
RS20050796A (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
CN102805737A (en) | Lansoprazole enteric oral disintegrating tablet and preparation method thereof | |
RU2015106931A (en) | MEDICINE FOR GASTROESOPHAGEAL REFLUX DISEASE | |
EA200701499A1 (en) | DOSAGE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
Oh | Pharmacological therapy of peptic ulcer | |
RU2006132127A (en) | APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR | |
JP2008525314A5 (en) | ||
RU2007129408A (en) | METHOD OF GROWING PIGS IN THE PERIOD OF FEEDING | |
RU2005101299A (en) | EMERGENCY FIRST-AID KIT AND MUTUAL AID KIT FOR BLEEDING FROM THE ESOPHAGULA, STOMACH AND DUODENAL | |
WO2006137839A3 (en) | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880100816.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08794829 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2694602 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010519222 Country of ref document: JP Ref document number: MX/A/2010/001071 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008282900 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008794829 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008282900 Country of ref document: AU Date of ref document: 20080725 Kind code of ref document: A |